ASPET

SEPTEMBER 16, 2024

Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact BBB. GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage.

Pharmacogenetics 100

Pharmacogenetics DNA Pharmacokinetics Treatment 100

ASPET

APRIL 16, 2024

Organic anions (OA) are compounds including drugs or toxicants that are negatively charged at physiological pH and are typically transported by Organic Anion Transporters (OATs). Human OAT4 (SLC22A11) is expressed in the apical membrane of renal proximal tubules.

Pharmacogenetics 100

Pharmacogenetics Drugs 100

ASPET

OCTOBER 20, 2023

This study aimed to evaluate the effects of cytochrome P450 3A4 (CYP3A4) gene polymorphism and drug interaction on the metabolism of blonanserin. Human recombinant CYP3A4 was prepared using the Bac-to-Bac baculovirus expression system.

Pharmacogenetics 100

Pharmacogenetics Drugs 100

ASPET

OCTOBER 12, 2023

Achieving adequate exposure of a therapeutic agent at the target is a critical determinant of efficacious chemotherapy. With this in mind, a major challenge in developing therapies for central nervous system (CNS) tumors is to overcome barriers to delivery, including the blood-brain barrier (BBB).

Pharmacogenetics 100

Pharmacogenetics Clinical Trials Treatment Therapies 100

ASPET

JUNE 10, 2024

Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. Ataxia telangiectasia mutated (ATM) kinase is a key regulator of DSB repair, and ATM inhibitors are being explored as radiosensitizers for various tumors, including primary and metastatic brain tumors.

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Treatment DNA 100

ASPET

AUGUST 4, 2023

Neuroblastoma (NB) is a pediatric cancer with low survival rates in high-risk patients. 131 I-mIBG has emerged as a promising therapy for high-risk NB and kills tumor cells by radiation. Consequently, 131 I-mIBG tumor uptake and retention are major determinants for its therapeutic efficacy.

Pharmacogenetics 100

Pharmacogenetics Therapies Disease 100

ASPET

JANUARY 31, 2024

We recently showed that riboflavin is a selected substrate of BCRP over P-gp and demonstrated its prediction performance in preclinical DDI studies. The aim of this study was to investigate the suitability of riboflavin to assess BCRP inhibition in humans.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics Drug Development Drugs 100

ASPET

NOVEMBER 17, 2023

Creatinine, a clinical marker for kidney function, is predominantly cleared by glomerular filtration, with active tubular secretion contributing to about 30% of its renal clearance.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics Disease Drugs 100

The Open Targets Blog

MAY 9, 2024

In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Pharmacogenetics examines the link between genetics and drug response, helping in the prioritisation of drug targets that minimise the risk of adverse effects.

Pharmacogenetics 72

Pharmacogenetics Drugs Therapies Disease 72

The Pharma Data

OCTOBER 27, 2020

Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). Two global pharmaceutical clients are also piloting the technology.

Pharmacogenetics 40

Pharmacogenetics Laboratories Therapies Hospitals 40

ASPET

MARCH 6, 2024

The organic anion transporting polypeptide (OATP) 2B1 (gene name SLCO2B1 ) is an uptake transporter that facilitates cellular accumulation of its substrates. In order to assess the in vivo relevance of the transporter, we applied SLCO2B1 +/+ knock-in and Slco2b1 -/- knock-out rats.

Protein Expression 100

Protein Expression Pharmacogenetics Treatment Drugs 100

ASPET

AUGUST 4, 2023

The natural product goldenseal is a clinical inhibitor of CYP3A activity, as evidenced by a 40-60% increase in midazolam AUC after coadministration with goldenseal. The predominant goldenseal alkaloids berberine and (-)-β-hydrastine were previously identified as time-dependent CYP3A inhibitors using human liver microsomes.

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Production Drugs 100

The Pharma Data

OCTOBER 27, 2020

The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research.

Pharmacogenetics 52

Pharmacogenetics Laboratories Clinical Research FDA 52